NEW YORK (TheStreet) -- Shares of Sanofi (SNY) - Get Report were advancing in late-afternoon trading on Thursday as the company is expected to report 2016 fiscal third-quarter results before tomorrow's opening bell.
Analysts surveyed by FactSet are looking for adjusted earnings of 85 cents per share and $10.44 billion in revenue.
During the same period last year, the French pharmaceutical company reported adjusted earnings of 88 cents per share on revenue of $10.51 billion.
Additionally, Sanofi announced today that it's adding Brazilian research organization Fiocruz to its existing partnership with the Walter Reed Army Institute of Research to speed up development of a Zika vaccine.
A vaccine could come to market in as little as two years, according to Reuters.
The World Health Organizationin February declared a global public health emergency after the Zika virus was identified as being linked to the birth defect microcephaly.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
The team rates Sanofi as a Hold with a ratings score of C+. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, the team also finds weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself.
You can view the full analysis from the report here: SNY